EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clinical and Molecular Hepatology · 01.04.2023 · 29 (2) · 320-331

DOI: 10.3350/cmh.2022.0422 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2023. Verfasst von Shang-Chin Huang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Science and Technology Council, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk factor for adverse liver outcomes like cirrhosis and hepatocellular carcinoma, its interactions with the hepatitis B virus (HBV) and clinical impacts seem complex. The presence of hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated liver injury. In contrast, the associated co-morbidities like diabetes mellitus or obesity may increase the risk of developing adverse liver outcomes. These findings implicate that components of MAFLD may have diverse effects on the clinical manifestations of CHB. To this end, a clinical strategy is proposed for managing patients with concurrent CHB and MAFLD. This review article discusses the updated evidence regarding disease prevalence, interactions between steatosis and HBV, clinical impacts, and management strategies, aiming at optimizing holistic health care in the CHB population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicNon-alcoholic Fatty Liver DiseaseLiver NeoplasmsHumansRisk FactorsLiver Cirrhosis

Stichwörter der Autor:innen

Fatty liverHepatitis B virusHepatocellular carcinomaMetabolic syndromeNon-alcoholic fatty liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

Förderung

  • National Science and Technology Council
  • Ministry of Health and Welfare

Zitieren

APA

Huang, S. C., & Liu, C. J. (2023). Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clinical and Molecular Hepatology, 29(2), 320-331. https://doi.org/10.3350/cmh.2022.0422

Vancouver

Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clinical and Molecular Hepatology. 2023;29(2):320-331. doi:10.3350/cmh.2022.0422

BibTeX
@article{Huang2023,
  author = {Huang, Shang-Chin and Liu, Chun-Jen},
  title = {Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives},
  journal = {Clinical and Molecular Hepatology},
  year = {2023},
  volume = {29},
  number = {2},
  pages = {320--331},
  doi = {10.3350/cmh.2022.0422}
}
Kostenlos starten →